Home > Boards > US Listed > Biotechs > Cellectar Biosciences Inc. (CLRB)

6 more days to wait for fog to clear:

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Crusader Member Profile
 
Followed By 91
Posts 5,746
Boards Moderated 0
Alias Born 06/05/08
160x600 placeholder
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 7/6/2020 6:32:07 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/6/2020 6:30:18 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/1/2020 4:02:31 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/25/2020 4:24:47 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/25/2020 4:24:05 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/25/2020 4:23:45 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/25/2020 4:22:59 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/25/2020 4:22:13 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/25/2020 4:02:12 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 6/12/2020 4:19:04 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 6/12/2020 4:10:12 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/11/2020 4:35:08 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 6/10/2020 6:33:36 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/8/2020 4:12:59 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/8/2020 4:09:44 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/8/2020 4:09:04 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/8/2020 4:08:23 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/5/2020 4:31:08 PM
Prospectus Filed Pursuant to Rule 424(b)(4) (424b4) Edgar (US Regulatory) - 6/4/2020 6:03:01 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/3/2020 9:15:54 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 6/3/2020 6:01:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/1/2020 8:31:01 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/26/2020 8:15:53 AM
Free Writing Prospectus - Filing Under Securities Act Rules 163/433 (fwp) Edgar (US Regulatory) - 5/20/2020 6:31:53 AM
Securities Registration Statement (s-1/a) Edgar (US Regulatory) - 5/20/2020 6:05:50 AM
Crusader   Thursday, 02/13/20 03:59:41 PM
Re: None
Post # of 7991 
6 more days to wait for fog to clear:

Cellectar Biosciences to Host a CLR 131 Clinical Data Call with Its Phase 2 Lead Investigator on February 19, 2020

BY GlobeNewswire
— 8:00 AM ET 01/09/2020

FLORHAM PARK, N.J., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences ( CLRB
Cellectar Biosciences, Inc. , a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that it will host a Clinical Data Call on Wednesday, February 19, 2020 at 10:30 am Eastern Time.

Members of Cellectar’s senior management team and Dr. Sikander Ailawadhi, M.D., the lead investigator for the company’s Phase 2 study, will provide additional clinical data, as well as an update and analysis of the CLR 131 Phase 1 and Phase 2 hematology focused trials. The team will also provide a summary of the data for patients with relapsed/refractory B-cell malignancies, including patients with multiple myeloma and select non-Hodgkins lymphoma. Additionally, the team will review the current treatment landscape and unmet medical need for treating patients with these cancers, and provide an overview of the market opportunity and its clinical development plan for CLR 131.

Sikander Ailawadhi, M.D. is an Associate Professor, Division of Hematology/Oncology at Mayo Clinic Florida and is the lead investigator for the company’s Phase 2 CLOVER-1 trial of CLR 131 in patients with relapsed/refractory B-cell hematologic cancers. Dr. Ailawadhi was awarded the 2013 NCI CCITLA as an Assistant Professor of Medicine at the Norris Cancer Center, University of Southern California (USC), Los Angeles CA. Subsequently, he joined the Division of Hematology and Oncology at Mayo Clinic in Florida as a Senior Associate Consultant in order to pursue his career goal of clinical, translational and outcomes-based research in B-cell malignancies, especially plasma cell disorders.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist